Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Vav2 CRISPR/Cas9 KO Plasmid (m): sc-423656
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Vav2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Vav2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Vav2 Antibody (F-6): sc-271442
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vav2 CRISPR/Cas9 KO Plasmid (m) | sc-423656 | 20 µg | $397.00 |
Overview
Vav2 encodes a guanine nucleotide exchange factor (GEF) for Rho family GTPases, linking receptor tyrosine kinase and integrin signaling to activation of Rac1 and related pathways. By coordinating actin cytoskeleton remodeling, cell adhesion, and membrane trafficking, VAV2 influences migration, spreading, and growth factor–dependent responses. In mouse systems, Vav2 is studied in immune and vascular biology as well as neuronal and epithelial contexts where cytoskeletal dynamics shape tissue homeostasis. Dysregulated VAV2 signaling has been implicated in aberrant proliferation and invasion phenotypes and is used as a mechanistic node in models of oncogenic and inflammatory signaling.
Vav2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Vav2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Vav2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Vav2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Vav2 protein expression.
This CRISPR knockout system enables efficient generation of Vav2-deficient cell models for investigation of Vav2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Vav2 exon(s) critical for Vav2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Vav2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Vav2 CRISPR/Cas9 KO Plasmid (m) and Vav2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Vav2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Vav2 HDR Plasmid (m) and Vav2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Vav2 homology arms to support homology-directed repair at defined Vav2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.